ADC Therapeutics (ADCT) EBT: 2019-2023
Historic EBT for ADC Therapeutics (ADCT) over the last 5 years, with Sep 2023 value amounting to -$45.4 million.
- ADC Therapeutics' EBT rose 11.53% to -$45.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$157.8 million, marking a year-over-year decrease of 17.31%. This contributed to the annual value of -$154,661 for FY2022, which is 38.51% up from last year.
- According to the latest figures from Q3 2023, ADC Therapeutics' EBT is -$45.4 million, which was up 13.85% from -$52.7 million recorded in Q2 2023.
- ADC Therapeutics' 5-year EBT high stood at -$20,190 for Q4 2022, and its period low was -$126.5 million during Q2 2020.
- In the last 3 years, ADC Therapeutics' EBT had a median value of -$51.4 million in 2021 and averaged -$44.3 million.
- As far as peak fluctuations go, ADC Therapeutics' EBT crashed by 478,797.94% in 2020, and later spiked by 65.32% in 2022.
- Quarterly analysis of 5 years shows ADC Therapeutics' EBT stood at -$35,170 in 2019, then plummeted by 65,329.79% to -$20.3 million in 2020, then crashed by 251.21% to -$56,352 in 2021, then soared by 64.17% to -$20,190 in 2022, then climbed by 11.53% to -$45.4 million in 2023.
- Its last three reported values are -$45.4 million in Q3 2023, -$52.7 million for Q2 2023, and -$59.7 million during Q1 2023.